Facet Hypertrophy | Diagnosis & Disease Information
WEBSep 12, 2022 · Etiology and Risk Factors. Spondylosis, or degeneration of the spine, is the most common cause of facet joint disease. Osteoarthritis, or degeneration that is due to natural wear and tear, is a process that involves cytokines and proteolytic enzymes. Other causes of facet hypertrophy can include trauma caused by car accidents, sports injuries, or …
2022 ACR/AAHKS Guidelines for Management of
WEBApr 6, 2022 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty: guideline summary.
Hydroxyapatite Crystal Deposition Disease (HADD)
WEBNov 15, 2022 · History and Epidemiology. A typically uniarticular condition, hydroxyapatite (HA) crystal deposition disease (HADD) is marked by the presence of hydroxyapatite crystals in the periarticular soft tissues, especially the tendons 1.HA is a mineral found in normal bone, but when it builds up in and around the joints it can cause inflammation, tenderness, and pain.
Viscosupplementation for Knee Osteoarthritis - Rheumatology …
WEBMar 25, 2019 · Knee osteoarthritis affects at least 19% of US adults 45 years old and older. While no cure for knee osteoarthritis has been found, there are treatment options available to help people stay active and manage their pain.
2019 EULAR/ACR Recommendations for SLE Classification Criteria
WEBSep 11, 2019 · Recommendations for Immunologic Domains and Criteria. Antiphospholipid Antibodies Criteria. Antiphospholipid antibody tests were added to the 2012 SLICC classification criteria, and the presence of any 1 of the following are included in the EULAR/ACR recommendations to increase sensitivity: anticardiolipin antibodies (immunoglobulin [Ig]A, IgG, or IgM) at medium or high titers, positive anti ...
Ehlers-Danlos Syndrome - Rheumatology Advisor
WEBEhlers-Danlos syndrome is a group of inherited connective tissue disorders that primarily affects the skin, joints, and blood vessel walls1 but can affect every organ system and result in significant morbidity and mortality. Typical clinical manifestations are skin hyperelasticity, hypermobility of joints, the fragility of blood vessels, and atrophic scarring. Hypermobility Ehlers-Danlos ...
Rheumatoid Arthritis Injection Treatment Approved by FDA
WEBJun 5, 2017 · Regeneron Pharmaceuticals, Inc., and Sanofi announced that the US Food and Drug Administration (FDA) has approved Kevzara (sarilumab) injection to treat adults with moderate to severe rheumatoid arthritis (RA).. This treatment is recommended in patients with RA who have had an inadequate response or demonstrated intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), such as ...
Drug-Induced Lupus | Diagnosis & Disease Information
WEBAug 4, 2022 · Epidemiology. Drug-induced lupus occurs in people who take certain types of medication but it is not considered a drug side effect. 1, 2 Flare ups caused by medications taken for pre-existing or latent lupus are excluded from this diagnosis. 1 With drug-induced lupus, specific drugs trigger an autoimmune reaction and the production of autoantibodies. 3 There are three types of drug-induced ...
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
WEBAug 9, 2022 · Undifferentiated connective tissue disease (UCTD) is a diagnosis of exclusion. Patients who present with clinical and serolotical manifestations that suggest a systemic autoimmune disease but do not fulfill criteria for defined connective tissue disease (eg, systemic lupus erythematosus, scleroderma, myositis, rheumatoid arthritis, Sjogren's syndrome) are classified to have UCTD.
Choosing the Right TNF Inhibitor Therapy for Rheumatoid Arthritis
WEBDec 20, 2017 · Biologics, approved nearly 20 years ago for the treatment of rheumatoid arthritis (RA), transformed treatment, and tumor necrosis factor inhibitors (TNFis) are now usually the first and most frequently used biologics. 1. Although all TNFis block TNFα and are broadly similar in efficacy and toxicity, resulting in little preference of one over another, there are important differences in TNFis ...